Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on TherapeuticsMD (TXMD) today and set a price target of $27. The company’s shares closed yesterday at $5.53.
Chen observed:
“We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.8% and a 40.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on TherapeuticsMD is a Moderate Buy with an average price target of $20.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $3.51. Currently, TherapeuticsMD has an average volume of 3.32M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
